Used primarily as a key intermediate in the synthesis of immunomodulatory drugs, particularly in the development of cereblon E3 ligase modulators. It plays a critical role in the production of targeted protein degradation therapeutics, including analogs of lenalidomide and pomalidomide. Its structure enables selective binding to cereblon, facilitating the degradation of disease-causing proteins, making it valuable in oncology research, especially for hematological cancers like multiple myeloma and myelodysplastic syndromes. Also employed in the preparation of PROTACs (proteolysis-targeting chimeras) due to its ability to recruit E3 ubiquitin ligase.